Skip to main content
    R

    Regeneron Pharmaceuticals Inc (REGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $952.40
    -3.07 (-0.32%)

    Market Cap: $98.84B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Regeneron Pharmaceuticals Inc (REGN) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in US dollars.

    Regeneron Pharmaceuticals reported revenue of $14.34B for the fiscal year ended Dec 31, 2025, up 1.0% from the year before. That year, net income was $4.50B with a net margin of 31.4%, operating cash flow was $4.98B and free cash flow was $4.08B. The quarter ended Sep 30, 2026 had revenue of $5.12B and net income of $1.95B.

    Revenue and Margins

    The operating margin was 24.9% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $4.86B, a compound annual rate of 12.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$14.34B+1.0%85.4%24.9%31.4%
    Dec 2024$14.20B+8.3%86.1%28.1%31.1%
    Dec 2023$13.12B+7.8%86.2%30.9%30.1%
    Dec 2022$12.17B-24.3%87.2%38.9%35.6%
    Dec 2021$16.07B+89.1%84.8%55.7%50.2%
    Dec 2020$8.50B+29.6%86.8%42.1%41.3%
    Dec 2019$6.56B+27.4%88.3%33.7%32.3%
    Dec 2018$5.15B-12.4%91.9%49.3%47.5%
    Dec 2017$5.87B+20.8%93.2%35.4%20.4%
    Dec 2016$4.86BN/A93.8%27.4%18.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 2.0% from the year before. In the quarter ended Sep 2026, net income rose 33.6% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$14.34B$14.20B$13.12B$12.17B$16.07B$8.50B$6.56B$5.15B$5.87B$4.86B
    Cost of revenue$2.10B$1.97B$1.82B$1.56B$2.44B$1.12B$765.10M$417.50M$397.10M$299.70M
    Gross profit$12.24B$12.23B$11.30B$10.61B$13.63B$7.38B$5.79B$4.73B$5.48B$4.56B
    Research and development$5.97B$5.23B$4.63B$3.85B$2.91B$2.73B$2.45B$1.47B$2.08B$2.05B
    Operating income$3.58B$3.99B$4.05B$4.74B$8.95B$3.58B$2.21B$2.53B$2.08B$1.33B
    Net income$4.50B$4.41B$3.95B$4.34B$8.08B$3.51B$2.12B$2.44B$1.20B$895.50M
    EBITDA$5.82B$5.32B$4.69B$5.26B$9.67B$4.10B$2.67B$2.73B$2.25B$1.44B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$5.12B$4.29B$3.61B$3.88B$3.75B$3.68B$3.03B$3.79B$3.72B$3.55B$3.15B$3.43B
    Gross profit$4.54B$3.71B$2.94B$3.30B$3.23B$3.15B$2.56B$3.22B$3.23B$3.07B$2.71B$2.92B
    Operating income$2.05B$1.29B$642.90M$879.90M$1.03B$1.08B$591.70M$990.20M$1.18B$1.07B$751.40M$972.90M
    Net income$1.95B$1.30B$727.20M$844.60M$1.46B$1.39B$808.70M$917.70M$1.34B$1.43B$722.00M$1.16B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $2.02B by $1.09B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$40.56B$37.76B$33.08B$29.21B$25.43B$17.16B$14.81B$11.73B$8.76B$6.97B
    Current assets$18.02B$18.66B$19.48B$15.88B$14.01B$9.78B$7.69B$6.45B$4.33B$3.18B
    Cash and equivalents$3.12B$2.49B$2.73B$3.11B$2.89B$2.19B$1.62B$1.47B$812.70M$535.20M
    Total liabilities$9.30B$8.41B$7.11B$6.55B$6.67B$6.14B$3.72B$2.98B$2.62B$2.52B
    Short-term debt$37.80MN/AN/A$720.00M$719.70M$1.63BN/A$90.80M$468.83M$129.56M
    Long-term debt$1.99B$1.98B$1.98B$1.98B$1.98B$1.98B$0N/A$703.45M$351.57M
    Shareholder equity$31.26B$29.35B$25.97B$22.66B$18.77B$11.03B$11.09B$8.76B$6.14B$4.45B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$44.41B$41.73B$40.87B$40.56B$40.17B$38.22B$37.55B$37.76B$37.44B$36.09B$34.37B$33.08B
    Total liabilities$10.91B$10.02B$9.45B$9.30B$9.21B$8.28B$8.16B$8.41B$8.12B$7.88B$7.38B$7.11B
    Cash and equivalents$3.66B$2.46B$2.96B$3.12B$2.51B$2.00B$3.09B$2.49B$2.01B$1.92B$2.60B$2.73B
    Shareholder equity$33.50B$31.71B$31.42B$31.26B$30.96B$29.94B$29.39B$29.35B$29.33B$28.21B$26.99B$25.97B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 81.9% of operating cash flow. Dividends and share repurchases together came to 93.4% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$4.98B$4.42B$4.59B$5.01B$7.08B$2.62B$2.43B$2.20B$1.31B$1.49B
    Capital expenditures$898.40M$755.90M$718.60M$590.10M$551.90M$614.60M$429.60M$383.10M$272.60M$511.90M
    Free cash flow$4.08B$3.66B$3.88B$4.42B$6.53B$2.00B$2.00B$1.81B$1.03B$974.00M
    Dividends paid$370.30M$0$0N/AN/AN/AN/AN/A$358.69M$500.18M
    Share repurchases$3.44B$2.60B$2.23B$2.08B$1.65B$5.85B$275.90M$4.40M$0$643.40M
    Investing cash flow-$629.10M-$2.47B-$3.19B-$3.78B-$5.38B-$70.60M-$2.03B-$1.46B-$1.01B-$1.05B
    Financing cash flow-$3.72B-$2.20B-$1.79B-$1.01B-$1.01B-$1.97B-$252.10M-$77.10M-$24.40M-$700.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$1.78B$813.00M$1.08B$1.17B$1.62B$1.14B$1.05B$1.26B$1.29B$354.00M$1.51B$1.09B
    Capital expenditures$300.20M$240.20M$230.60M$248.70M$201.40M$219.00M$229.30M$199.60M$241.90M$180.50M$133.90M$251.40M
    Free cash flow$1.48B$572.80M$848.30M$922.00M$1.42B$925.40M$815.80M$1.06B$1.05B$173.50M$1.38B$838.30M
    Last 12 quarters

    Frequently Asked Questions About REGN

    What is Regeneron Pharmaceuticals' annual revenue?

    Regeneron Pharmaceuticals reported revenue of $14.34B for the fiscal year ended Dec 31, 2025.

    How fast is Regeneron Pharmaceuticals' revenue growing?

    Revenue was up 1.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.6%.

    Is Regeneron Pharmaceuticals profitable?

    Yes. Regeneron Pharmaceuticals reported net income of $4.50B for the fiscal year ended Dec 31, 2025, with a net margin of 31.4%.

    How much free cash flow does REGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $4.98B minus capital expenditures of $898.40M produced free cash flow of $4.08B.

    How much debt does Regeneron Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.99B, short-term debt of $37.80M and cash and equivalents of $3.12B.